ImmunoGen

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. Leading healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies, and Roche's marketed product, Kadcyla, utilizes ImmunoGen's ADC technology.
Type
Public
HQ
Waltham, US
Founded
1981
Employees
317 (est)+6%

Key People at ImmunoGen

Gregory D. Perry

Gregory D. Perry

EVP & CFO
Daniel M. Junius

Daniel M. Junius

President & CEO
Stephen C. McCluski

Stephen C. McCluski

Chairman

ImmunoGen Locations

Waltham, US
Norwood, US
Brentwood, US

ImmunoGen Metrics

ImmunoGen Summary

Founding Date

1981

Market capitalization

$164 M

Closing share price

$1.77

ImmunoGen Market Value History

ImmunoGen Company Life

You may also be interested in